IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
93 hedge funds and large institutions have $487M invested in IGM Biosciences in 2022 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 19 reducing their positions, and 21 closing their positions.
90% more call options, than puts
Call options by funds: $15M | Put options by funds: $7.91M
74% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 19
29% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 21
7% more funds holding
Funds holding: 87 → 93 (+6)
2.34% more ownership
Funds ownership: 67.77% → 70.11% (+2.3%)
5% less capital invested
Capital invested by funds: $514M → $487M (-$26.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$9.31M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.73M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.56M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.72M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$27.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$10.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.33M |
| 4 |
EGP
Entrust Global Partners
New York
|
-$1.94M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.82M |
IGMS Hedge Fund Activity: Q1 2022 in Review
93 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2022, worth a combined $487M — down 5.2% from $514M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new IGMS positions and 21 closed out — a net gain of 6 holders — while 33 added to existing stakes and 19 trimmed.
The largest buyer was Artal Group, adding an estimated $9.31M. The largest seller was Pictet Asset Management (Switzerland), exiting entirely with an estimated $27.4M sold.
- 93 institutional investors held IGM Biosciences (IGMS) as of Q1 2022, up from 87 in Q4 2021.
- Funds reported $487M of IGM Biosciences stock for Q1 2022, down 5.2% quarter-over-quarter.
- 27 funds opened new IGM Biosciences positions in Q1 2022 and 21 closed out, a net change of +6 holders.
- The largest IGM Biosciences buyer in Q1 2022 was Artal Group, an estimated $9.31M added.
- The largest IGM Biosciences seller in Q1 2022 was Pictet Asset Management (Switzerland), an estimated $27.4M sold.
Based on aggregated 13F filings for Q1 2022.